[1]Glecirasib Receives Breakthrough Therapy Designation in China for KRAS G12C–Mutated Pancreatic Cancer.https://www.onclive.com/view/glecirasib-receives-breakthrough-therapy-designation-in-china-for-kras-g12c-mutated-pancreatic-cancer [2]Li J, Zhao J, Cao B, et al. A phase I/II study...
[1]Glecirasib Receives Breakthrough Therapy Designation in China for KRAS G12C–Mutated Pancreatic Cancer.https://www.onclive.com/view/glecirasib-receives-breakthrough-therapy-designation-in-china-for-kras-g12c-mutated-pancreatic-cancer [2]Li J, Zhao J, Cao B, et al. A phase I/II study...
14. Muzumdar MD, Chen P-Y, Dorans KJ, et al. Survival of pancreatic cancer cells lacking KRAS function. Nat Commun. 2017;8(1):1090. 15. Hallin J, Engstrom LD, Hargis L, et al. The KRASG12C inhibitor MRTX849 provides insigh...
2.Muzumdar MD, Chen P-Y, Dorans KJ, et al. Survival of pancreatic cancer cells lacking KRAS function. Nat Commun. 2017;8(1):1090. 3.Hallin J, Engstrom LD, Hargis L, et al. The KRASG12C inhibitor MRTX849...
索托拉西布显示出一定的抗肿瘤活性，并且在先前接受过治疗的KRAS p.G12C-突变型晚期胰腺癌患者中具有可接受的安全性。延申阅读 PARPi联合ICIs治疗胰腺癌丨合成致死与免疫检查点的双向协同 参考文献 Strickler JH, et al. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. N Engl J Med. 2022 ...
2023年12月26日，来自美国康奈尔医学院的陈水冰团队在Cell Stem Cell 杂志上发表题为 A Pancreatic Cancer Organoid Platform Identifies an Inhibitor Specific to Mutant KRAS的文章。他们开发了一组等基因小鼠胰腺类器官平台，其中包含常见的 PDAC 驱动突变 KRASG12D、Tp53R172H 和 SMAD4 缺失。基于这一胰腺类器官...
宾夕法尼亚医学院艾布拉姆森癌症中心的研究人员2022年12月06日在《Cancer Discovery》 发表研究成果Efficacy of a small molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer（DOI: 10.1158/2159-8290.CD-22-1066），研究法人发现了一种小分子抑制剂攻击难以靶向的致癌基因突变KRAS，在...
14. Muzumdar MD, Chen P-Y, Dorans KJ, et al. Survival of pancreatic cancer cells lacking KRAS function. Nat Commun. 2017;8(1):1090. 15. Hallin J, Engstrom LD, Hargis L, et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in...
2.Muzumdar MD, Chen P-Y, Dorans KJ, et al. Survival of pancreatic cancer cells lacking KRAS function. Nat Commun. 2017;8(1):1090. 3.Hallin J, Engstrom LD, Hargis L, et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mous...
KRAS是人类癌症中最常见的突变癌基因,约17%的实体肿瘤有KRAS突变,包括约90%的胰腺癌、50%的结肠癌和25%的肺腺癌。常见的KRAS突变包括G12C、G12D、G12V等。 在科学家及药物研发人员的多年努力下,KRAS已不再是不可成药靶点,目前FDA已经批准了两款KRAS G12C抑制剂上市,用于治疗非小细胞肺癌,但携带G12D、G12V...